MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ
2.250
+0.030
+1.35%
After Hours: 2.250 0 0.00% 19:30 10/09 EDT
OPEN
2.230
PREV CLOSE
2.220
HIGH
2.307
LOW
2.140
VOLUME
904.87K
TURNOVER
--
52 WEEK HIGH
3.720
52 WEEK LOW
1.700
MARKET CAP
161.16M
P/E (TTM)
-1.4239
1D
5D
1M
3M
1Y
5Y
1D
Nkarta: NKX019 Autoimmune Safety and Early Efficacy Support Reiterated Buy Rating and Unchanged $11 Price Target
TipRanks · 10/05 11:25
Weekly Report: what happened at NKTX last week (0928-1002)?
Weekly Report · 10/05 10:18
Nkarta (NKTX) Receives a Buy from Stifel Nicolaus
TipRanks · 09/28 10:56
Weekly Report: what happened at NKTX last week (0921-0925)?
Weekly Report · 09/28 10:14
H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)
TipRanks · 09/22 09:45
Weekly Report: what happened at NKTX last week (0914-0918)?
Weekly Report · 09/21 10:14
Weekly Report: what happened at NKTX last week (0907-0911)?
Weekly Report · 09/14 10:19
Nkarta Insiders Got A Good Deal Selling At US$2.10
Simply Wall St · 09/09 10:11
More
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.

Webull offers Nkarta Inc stock information, including NASDAQ: NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.